Eisai to buy TorreyPines' Alzheimer's genetic research
This article was originally published in Scrip
Executive Summary
Eisaihas ended its collaborations with TorreyPines Therapeutics for basic research into the genetic mechanisms of Alzheimer's disease, and is to acquire all data and assets from the programmes. These looked at genes related to late-onset disease (which ended in September 2005) and whole-genome screening to elucidate pathogenesis (this September). Eisai will pay an undisclosed cash amount to the US firm, which is looking to progress several clinical-stage programmes. TorreyPines is also working on in-house gamma secretase modulators for Alzheimer's, for which it is seeking a development partner.